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Broad blocking of MDR efflux 
pumps by acetylshikonin and 
acetoxyisovalerylshikonin to 
generate hypersensitive phenotype 
of malignant carcinoma cells
Seyed Abbas Mirzaei1, Somayeh Reiisi2, Parmida Ghiasi Tabari1, Abolfazl Shekari3, Fatemeh 
Aliakbari4, Elaheh Azadfallah4 & Fatemeh Elahian  5
Cytotoxic activities of acetylshikonin and acetoxyisovalerylshikonin alone and in combination with 
chemotherapeutic agents against parental and drug resistant cell lines were determined using the 
MTT assay. Effects of Shikonin derivatives on BCRP, MDR1 and MRP transcript and protein levels were 
relatively measured. Finally, accumulation and efflux kinetics were conducted. The results revealed cell- 
and concentration-dependency of the cell cytotoxicity. Acetylshikonin and acetoxyisovalerylshikonin 
transiently made the mRNA ocean turbulent, but FACS analyses using fluorescent-labeled antibodies 
showed no significant change in the MDR-protein levels. Functional kinetics revealed significant block 
of MDR1, BCRP and MRP transporter in the presence of shikonin derivatives. Maximum accumulation 
fold changes was quantified to be 4.4 and consequently, acetoxyisovalerylshikonin pretreated 
EPG85.257RDB cells was chemosensitized to daunorubicin tension 3.1-fold. Although, the MDR 
blockage was reported to follow time- and cell-dependent patterns, MDR1, BCRP and MRP2 responses 
to the shikonins are concentration-independent. These data suggest uncompetitive transporter 
blockage behavior of these agents. The results indicated that shikonin derivatives stimulate uptake and 
reduce efflux of chemotherapeutic agents in the malignant cancer cells, suggesting that chemotherapy 
in combination with shikonin compounds may be beneficial to cancer cells that overexpress multidrug 
resistance transporters.
Drug resistance is one of the main challenges in cancer chemotherapy and is influenced by several important 
factors which include drug potency, cancer cell response to the treatments, tumor microenvironment and heter-
ogeneity of cancer cells1,2. Multidrug resistance (MDR) or chemo-resistance represents an event whereby cancer 
cells exhibit tolerance to a specific chemotherapeutic agent or a class of pharmaceutical drugs3. Target-dependent, 
drug dependent, and drug/target-independent are the most common MDR phenotypes4,5. Overexpression of 
ATP-binding cassette (ABC) transporter superfamilies are the most significant mechanisms underlying MDR 
phenotype, which consume ATP and efflux either cytotoxic drugs or targeted anticancer agents6. The most prev-
alent ABC superfamily members are including P-glycoprotein (P-gp/ABCB1), multidrug resistance-associated 
protein (MRP/ABCC), and breast cancer resistance protein (BCRP/ABCG2), which may over-activated or 
up-regulated in malignant cancers, and develop a distinctive defense contradictory to chemotherapeutics. These 
pumps clearly reduce the intracellular concentration of frequent endotoxin and exotoxins, therefore causing 
MDR-phenotype7,8.
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Recently, many investigators explored herbal bioproducts such as the MDR cell chemosensitizers with least 
cytotoxicity. Some naturally active ingredients like carotenoid, coumarin, flavonoid, naphthoquinone, stilbenoid, 
and terpenoid derivatives obtained from plants and fungi have been previously reported as MDR modulators/
inhibitors9,10. Various studies have revealed that herbal extracts synergistically increased chemotherapy potency, 
reduced the chemotherapeutics doses, and increased therapeutic window of cytotoxic agents, especially via 
inverse MDR in cancer cells. These natural MDR-modulators mainly act as antagonists, reverse agonists, tran-
script down-regulators, protein down-regulators, metabolism modulators, or ATP binding interaction interferers 
which reduce chemotherapeutics efflux from the cancer cells10,11. Naphthazarins and their derivatives have been 
investigated for a variety of biological functions, such as antibacterial, antimalarial, antifungal and anticancer 
properties12,13.
Shikonin is one of the natural naphthazarins which is the major constituent of red extracts of the roots of 
Lithospermum erythrorhizon and Alkanna frigida and has been traditionally used for the treatment of sore throat, 
injuries, infections the and gastrointestinal disorders14,15. Shikonin derivatives including isobutyrylshikonin, 
acetylshikonin, dimethylacrylshikonin and isovalerylshikonin have also demonstrated selective anticancerous, 
tyrosine kinase inhibitory, ROS generation, anti-angiogenesis, proteasome inhibitory, anti-inflammatory and 
anti-glycolysis activities16,17. Earlier, shikonin was reported to downregulate MDR1 protein and chemosensitized 
cells resistance to chemotherapy18. There is little information on the modulatory mechanism of alkylated napht-
hazarin moieties on ABC-transporters, although, higher cancer cytotoxicity via acceleration of apoptotic protein 
production and triggering of death signaling receptors has been reported for some chemically modified shi-
konin derivatives16,19. Therefore, the present study mainly focused on the restrictive effects of two novel alkylated 
shikonin derivatives: acetylshikonin and β-acetoxyisovalerylshikonin, on ABC-transporter expression level and 
function in human cancer cell lines. These results present well-known compounds helpful in the management of 
malignant multidrug resistant cancers.
Results
In vitro cytotoxic behaviors of shikonins. Sensitivity of the parental cells and their MDR-resistant lines 
to shikonin derivatives and standard chemotherapeutic agents were measured. After a 5-day treatment with serial 
dilutions of chemical agents, a dose-response curve was fitted to the normalized MTT data (Supp. Fig. S1). Table 1 
shows the IC10 and IC50 values for acetylshikonin and acetoxyisovalerylshikonin and IC50 data for the chemother-
apeutic agents. Acetylshikonin presented higher toxicity than the acetoxyisovalerylshikonin for EPG85.257RDB 
and MCF7MX cell lines. Primary investigations revealed that shikonin derivatives inhibited cell growth time-, 
dose- and cell-dependently. In addition, the combination of shikonins with standard chemotherapeutics resulted 
in a statistical significant improvement of daunorubicin, mitoxantrone or cisplatin toxicity and confirmed syner-
gistic toxicity (P < 0.001, Tables 1 and 2). Acetylshikonin combination therapy mostly showed more prominent 
toxic effects on both parental and resistant cells. Dose-response curves illustrated significant decreases of viable 
cell fractions against higher concentrations of the combination therapy (Supp. Fig. S2).
MDR pump transcripts level and relative protein quantification. Relative BCRP, MDR1 and MRP 
transcript and protein quantities were measured using real time PCR and flow cytometer instruments according 
to the validated standard protocols. Real time based transcript quantifications was optimized on Pfaffl method 
using high effective primer pairs (Supp. Table S1). Initial experiments showed that MCF7MX, EPG85.257RDB 
and A2780RCIS cells express BCRP, MDR1 and MRP2 approximately 800-, 310- and 13-fold more than their 
corresponding parents, respectively. Totally, MDR1 and MRP1 transcripts were up-regulated in the resistant cells 
time-dependently and BCRP and MRP2 represented down-regulation patterns over time in these cells after shi-
konin treatments; however, this could not be generalized to all cells, treatments or times (Supp. Fig. S3). Parent 
cells generally follow the same expression patterns after treatments just like their resistant counterparts, even 
though they do not express sophisticated MDR pumps (Supp. Fig. S3). Relative BCRP protein quantifications 
showed up-regulation after 48 h of acetoxyisovalerylshikonin treatment (P < 0.05) and down-regulation after 72 h 
of acetylshikonin treatment (P < 0.05) in MCF7 cells; however, the resistant EPG85.257RDB and MCF7MX efflux 
protein fluctuations are statistically insignificant (P > 0.05) over a 3-day of shikonin exposure (Fig. 1).
Compounds EPG85.257 EPG85.257RDB MCF7 MCF7MX A2780 A2780RCIS
Acetylshikonin IC10 ± SEa 16.03 ± 2.01 0.91 ± 0.17 102.92 ± 7.71 31.92 ± 0.89 22.55 ± 5.10 51.78 ± 5.13
Acetoxyisovalerylshikonin IC10 ± SE 0.16 ± 0.11 4.16 ± 0.39 180.14 ± 9.19 108.42 ± 11.25 7.35 ± 1.18 10.32 ± 1.07
Acetylshikonin IC50 ± SE 49.51 ± 7.32 18.31 ± 2.76 363.56 ± 27.64 237.60 ± 44.21 73.90 ± 6.19 129.44 ± 11.71
Acetoxyisovalerylshikonin IC50 ± SE 1.24 ± 0.80 8.71 ± 2.04 >600 >600 21.44 ± 3.56 30.18 ± 4.35
Daunorubicin IC50 ± SE 0.06 ± 0.01 9.06 ± 1.14 ND ND 0.22 ± 0.01 0.21 ± 0.03
Cisplatin IC50 ± SE ND ND ND ND 1.83 ± 0.19 45.89 ± 1.19
Mitoxantrone IC50 ± SE ND ND 0.62 ± 0.02 6.46 ± 1.02 ND ND
Table 1. IC10 and IC50 values for shikonin derivatives and standard chemotherapeutics agents on the cancer 
cells. aDrug concentration (µM) necessary for 10% or 50% inhibition of cell growth after 5 days of drug 
treatment. Data display the mean ± standard error of three distinct experiments. The extrapolated IC50 values 
for acetoxyisovalerylshikonin for MCF7 and MCF7MX cells are 991 and 819 μM, respectively. ND, not defined.
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Accumulation and efflux kinetic. Effects of naphthazarin on the chemotherapeutics accumulation and 
efflux in the sensitive and resistant cell lines were flow cytometric evaluated. BCRP, MDR1 and MRP2 pump activ-
ity was significantly reduced in the acetylshikonin and acetoxyisovalerylshikonin treated MCF7/MX, EPG85.257/
RDB and A2780/RCIS cells, respectively (Fig. 2, Supp. Figs S4 and S5). Inconsequence, the shikonins led to a 
time-dependent accumulation of mitoxantrone and daunorubicin in the respective cells during the incubation 
periods (P < 0.001). Maximum daunorubicin and mitoxantrone accumulation was detected after 24 and 48 h 
of acetoxyisovalerylshikonin treatment of EPG85.257RDB and MCF7MX, respectively (P < 0.001). Although, 
both treatments showed a dynamic reduction in pumps efflux activity, acetoxyisovalerylshikonin resulted in 
more potent inhibitory activity (P < 0.001). Cells accumulation and efflux pattern of acetylshikonin treated 
EPG85.257RDB returned to the control levels after 72 h of drug exposure. MRP2 pump activity in A2780RCIS 
cells was less affected by both treatments in comparison with the other resistant cells (Fig. 2, Supp. Fig. S5).
Discussion
The main reason for numerous types of chemotherapy failure is overexpressing of MDR pumps in cancer cells20. 
Such cells frequently present increased ATP-dependent efflux pumps feature and demonstrate prominent ability 
of increased efflux and reduced influx21. Numerous herbal-derived extracts and pure constituents are known to 
increase the chemotherapeutic effects of anticancer agents by modulating the ABC-transporters’ transcription, 
translation, and activity as well as regulating cell survival, apoptotic signaling pathways, drug distribution, and 
cellular metabolisms which make them less toxic and promising candidates for targeting MDR resistance22–24.
It has been confirmed in the literature that shikonin derivatives exhibit antineoplastic properties mainly by 
cancer cell growth inhibition, apoptotic pathway induction, DNA topoisomerase interference, antimitogenic 
action, angiogenesis reduction, and proteasome inhibition25–27. Alkylated shikonin derivatives on C2 and C7 
showed stronger cytotoxicity on cancer cells rather than normal cells (Supp. Fig. S6). Reports showed that intro-
duction of oxygen-containing alkyls or cycloalkyls on C2 position enhanced the cytotoxicity effects against mul-
tiple drug resistant cancer cells18,28–30. Table 1 shows results consistent with previous studies and confirms that 
acetylshikonin and acetoxyisovalerylshikonin with higher levels of oxygen atoms exert remarkable toxic effects 
on both parental and resistant cancer cells. Although, presence of shorter alkyl groups (2–6 carbons) has been 
reported to have stronger antitumor activity than longer chains (7–20 carbons) in few researches31,32; such pat-
terns could not be extended to A2780/RCIS cells in the present study and Table 1 showed that shikonin toxicity is 
most likely cell specific. Table 2 presents the interaction of the new derivatives with normal metabolic pathways 
of MDR-resistant cells which is overall referred to as “Warburg effect”. The mechanisms that enhance this suscep-
tibility may include direct MDR-pump interference, cellular transcription and translation alteration, alteration of 
oxidoreductase enzymes, ATPase blockage, interruption of gaining energy in tumor cells through the glycolysis 
pathway, or enhancement of bioavailability of chemotherapeutics which has not been fully investigated yet33,34. 
Though Tables 1 and 2 shows attracting cytotoxic effects of two shikonin analogs on the multidrug resistant cells, 
evidences on the association between the structural relationship and desired functions of the derivatives remain 
unclear.
Preliminary results in this study showed up-regulation of MDR1 and MRP1, and down-regulation of BCRP 
and MRP2 pumps after naphthazarin treatments in the transcriptional levels as primary adaptation and xenobi-
otic detoxification responses; however, the translational pump levels remained unchanged, and such inconsist-
ency has been reported previously which could be attributed to post-transcriptional changes, the protein half-life 
and environmental conditions35–37. Besides, flow cytometric analyses showed that BCRP, MDR1 and MRP2 efflux 
function were significantly disrupted during the 72 h treatments (Fig. 2). Acetoxyisovalerylshikonin led to max-
imum 4-fold daunorubicin accumulation in EPG85.257RDB cells and the corresponding cell was sensitized to 
daunorubicin toxicity 3-fold. It can be concluded that increased drug accumulation inside these cells is possibly 
due to inhibition of pump activity after the treatment and resulted in chemotherapy sensitization. Interestingly, 
an appropriate balance was observed between efflux decrease and accumulation increase responses in the most 
resistant cells. Mitoxantrone and daunorubicin accumulation in respective MCF7MX and A2780RCIS were less 
affected by shikonin derivatives and the chemosensitization to the chemotherapeutics was also less observed. 
Compounds EPG85.257 EPG85.257RDB MCF7 MCF7MX A2780 A2780RCIS
Daunorubicin SIC50 ± SE and 
acetylshikonin 0.01 ± 0.01 1.85 ± 0.17 ND ND 0.07 ± 0.02 0.09 ± 0.01
Daunorubicin SIC50 ± SE and 
acetoxyisovalerylshikonin 0.02 ± 0.00 2.88 ± 0.14 ND ND 0.03 ± 0.01 0.176 ± 0.08
Mitoxantrone SIC50 ± SE and 
acetylshikonin ND ND 0.13 ± 0.04 9.24 ± 1.42 ND ND
Mitoxantrone SIC5 0 ± SE and 
acetoxyisovalerylshikonin ND ND 0.92 ± 0.16 8.16 ± 1.32 ND ND
Cisplatin SIC50 ± SE and 
acetylshikonin ND ND ND ND 5.23 ± 1.15 117.84 ± 10.81
Cisplatin SIC50 ± SE and 
acetoxyisovalerylshikonin ND ND ND ND 7.93 ± 1.04 135.83 ± 9.22
Table 2. Synergistic toxicity of standard chemotherapeutics agent on the cancer cells cotreated either with 
acetylshikonin or acetoxyisovalerylshikonin. aDaunorubicin, Mitoxantrone, or cisplatin concentrations (µM) 
required for 50% inhibition of cell growth after 5 days of drug exposure. Data represent the mean ± standard 
error of three distinct tests. ND, not defined.
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MCF7MX cells presented chemotoleration features for mitoxantrone cytotoxicity during both shikonin treat-
ments even though BCRP pump activity was significantly (P < 0.001) blocked during the experiment time. Such 
behaviors may be attributed to alteration of metabolism pathways of cancer cells associated with energy con-
sumption, chemotherapeutics metabolism and physicochemical inactivation of the hydroxyl naphthoquinones in 
this cell36,38. Our initial investigations demonstrated that chemosensitization and MDR-associated efflux blockage 
are less likely dependent on shikonin dosage volumes; such separate activities support the hypothesis that shi-
konins are uncompetitive pump blockers. This phenomenon may due to shikonin derivatives interference in ATP 
production, distribution or consumption36,39. Moreover, ATP transporters that actively efflux xenobiotics gain 
their energy in tumor cells through the glycolytic pathway. Maybe, inhibiting glycolysis in these cells may also 
increase the concentrations of chemotherapeutic agents in the cell34,40,41.
Conclusion
The results of the present study indicate that oxygenated shikonin derivatives have potently chemosensitized 
MDR1 overexpressing cancer cells to the daunorubicin treatment. ABC-transporter blockage follows time- and 
cell-dependent patterns but MDR1, BCRP and MRP2 responses to the shikonins are concentration-independent. 
Data suggest that naphthazarin derivatives may be effective uncompetitive transporter blockers. These findings 
introduced acetylshikonin and acetoxyisovalerylshikonin as attractive candidates for multidrug resistant cancers 
therapy in clinical practice. However, further investigations are required to uncover unique mechanism of actions 
and structural activity relationships underlying their effects on efflux transporter.
Materials and Methods
Reagents. The chemical were obtained from commercial resources. MTT, chemotherapeutic agents and 
MDR pump inhibitors were purchased from Sigma-Aldrich (Sigma-Aldrich, Deisenhofen, Germany). Cell cul-
ture media and components were purchased from Gibco (Grand Island, NY, USA). BCRP and MDR1, primary 
antibodies (mouse monoclonal IgG), goat anti-mouse secondary IgG1 and IgG2a conjugated with FITC, and the 
appropriate isotype controls were obtained from Abcam (Cambridge, USA). Shikonin analogous were generously 
provided by Professor Alireza Yazdinezhad (Zanjan University of Medical Sciences). All other compounds and 
solvents were of analytical grade and obtained from Merck Company (Darmstadt, Germany).
Figure 1. Relative quantification of MDR proteins using flow cytometer. MDR1 and BCRP protein levels 
of EPG85.257 and MCF7 parental and their resistant counterparts were quantified in the presence of 
acetylshikonin and acetoxyisovalerylshikonin. ACS, acetylshikonin; AVS, acetoxyisovalerylshikonin; Con, 
control.
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Cell culture and cell viability assays. A2780RCIS (MRP2 overexpressing human epithelial ovarian can-
cer), EPG85.257RDB (MDR1 overexpressing human gastric adenocarcinoma), MCF7MX (BCRP overexpressing 
human epithelial breast cancer), and their parental counterparts were generously provided by Professor Herman 
Lage (Molecular Pathology Department, University Medicine Berlin). Cells were cultured in RPMI-1640 supple-
mented with 2 mM L-glutamine, 10% FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin in a pre-equilibrated 
humidified incubator at 37 °C and 5% CO2. Media for multidrug resistant A2780RCIS, EPG85.257RDB and 
MCF7MX cell lines was also supplemented with 33.21 μM cisplatin, 4.74 μM daunorubicin or 0.10 μM mitox-
antrone, respectively. Shikonins cytotoxicity was determined after a 5-day incubation of the treated cells by MTT 
assay at 570 nm using microplate reader. IC10 and IC50 values were calculated from the scatter plot of the per-
centage viability versus drug concentrations and defined as the drug concentrations that reduced the surviving 
cells in the wells by 10 and 50% as compared to the control, respectively. Combination treatment of the cells with 
defined IC10 values of acetylshikonin and acetoxyisovalerylshikonin in the presence of serially diluted cisplatin, 
daunorubicin or mitoxantrone was also reported as synergistic cytotoxicity. SIC50 value was defined as the chem-
otherapeutic agent concentration that was co-treated with any of shikonins and reduced the surviving fraction 
of the cells by 50% when compared with the untreated cells. SIC50 was measured from scatter plot of relative cell 
viability versus any of the chemotherapeutic agent concentrations. All the experiments were accomplished three 
independent times in pentaplicate42.
Relative quantification of the MDR pump transcripts. Cells were seeded at 3 × 105 cells/well and 
treated with IC10 concentrations of acetylshikonin and acetoxyisovalerylshikonin for 24, 48, and 72 h before RNA 
Figure 2. Accumulation and efflux patterns of daunorubicin and mitoxantrone in MDR-resistant cells. 
Cells were incubated with IC10 values of acetylshikonin and acetoxyisovalerylshikonin for 24, 48 and 72 h 
and then treated with IC50 concentration of daunorubicin or mitoxantrone in the presence or absence of a 
specific inhibitor (indomethacin for MRP2 pumps, verapamil for MDR1 pumps or novobiocin for BCRP 
pumps). Average fluorescent intensities were recorded. Efflux and accumulation were calculated from 
corresponding equations. The symbols (***), (**)and (*) represent pump activity differences between 
shikonin treated and untreated cells as P < 0.001, P < 0.05 and P < 0.01, respectively. ACS, acetylshikonin; AVS, 
acetoxyisovalerylshikonin; Con, control.
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extraction. High quality total RNA was isolated (RNeasy Mini Kit, Qiagen) and cDNA was generated (QuantiTect 
Reverse Transcription Kit, Qiagen) from 1 μg RNA following the manufacturer’s instruction. Quantitative tran-
script analyses were conducted using the QuantiTect SYBR Green PCR kit (Qiagen, Germany). Real time ampli-
fication was set to an initial denaturation step for 10 min at 94 C, followed by 40 cycles of amplification (94 °C for 
15 s, annealing temperature for 20 s and 72 °C for 25 min) and finally, a normal melting analysis. BCRP, MDR1, 
MRP1, MRP2 and β-actin primer sequences and properties are provided in the supplementary materials. All 
the amplification reactions were performed in triplicate and results were normalized to β-actin, and relative fold 
changes in the expression were quantified according to Pfaffl method43.
Flow cytometry analyses of relative MDR pump levels. Resistant and parent cancer cells were treated 
with IC10 concentrations of acetylshikonin or acetoxyisovalerylshikonin for 24, 48, and 72 h in 6-well plates. 
Thereafter, the monolayer cells were trypsinized, harvested and finally fixed with formaldehyde (10% v/v) and 
cold methanol (90% v/v) for 10 min, respectively. Then, the cells were resuspended in blocking suspension of 10% 
w/v bovine serum albumin for 1 h at room temperature to minimize nonspecific antibody binding. EPG85.257, 
A2780, MCF7 resistant and parent cells were independently incubated in 0.01 v/v PBS-diluted primary anti-
body of either human BCRP, MDR1 or MRP2 supplemented with 2% BSA and 0.01% Tween-20 for 1 h at 4 °C. 
Subsequently, the cells were incubated in PBS buffer containing 0.01 v/v FITC-conjugated goat anti-mouse sec-
ondary immunoglobulin, 2% BSA, and 0.01% Tween-20 for 20 min on ice in the dark. PBS-washing was included 
twice between all steps. Subsequently, the protein levels were analyzed using a FACSCaliburTM flow cytometer 
with proper negative controls (autofluorescent, secondary antibody and isotype controls). Intact cells were sep-
arated from cellular debris using forward/side scatter parameters. FITC-labeled proteins were excited with the 
488 nm laser and the emission fluorescence intensity was recorded using photomultiplier tube with a 530/30 nm 
band-pass filter (FL1). Finally, data were processed using WinMDI (version 2.8) and FlowJo (version 7.6.1) for 3 
independent experiments as compared to the corresponding untreated controls42,43.
Effects of shikonin on chemotherapeutics accumulation and efflux kinetic. Briefly, the 
MDR-resistant cancerous cells and their parental counterparts were seeded at a density of 5 × 105/well in 6-well 
plates and incubated with IC10 values of acetylshikonin and acetoxyisovalerylshikonin for 24, 48 and 72 h. Then, 
the cells were harvested and divided into two individual groups. First one was treated with only fluorescent chem-
otherapeutic substrate (1 μM daunorubicin for MDR1 and MRP or 3 μM mitoxantrone for BCRP efflux pumps); 
the second one received a corresponding specific pump inhibitor also (10 μM verapamil for MDR1, 100 μM 
indomethacin for MRP or 200 μM novobiocin for BCRP) for 30 min at room temperature. Cells were harvested, 
PBS-washed and divided into portions. The first fractions were placed on ice and immediately, FACS analyzed 
for accumulation kinetics. The second fraction was treated with RPMI-1640 containing 10% FBS either with (for 
inhibitor-treated cells in the accumulation step) or without (for inhibitor-untreated cells in the accumulation 
step) pump inhibitor for another 1 h in the dark at room 37 °C. After PBS washing for efflux assay, these cells were 
subjected to FACS analyses. IC10 values of shikonin derivatives were presented in all the steps of kinetic assays. 
Forward/side scatter gating included the viable single cells of the study and the fluorophores were excited at 
488 nm. Daunorubicin and mitoxantrone emission was recorded at FL2 (585 nm) and FL3 (670 nm), respectively. 
105 events were recorded for samples and the following equations were used for the mathematical models where, 
MFI, modulator, sample and control are mean fluorescent intensity, pump inhibitors, shikonin treated cells and 
untreated cells, respectively. Appropriate negative controls were also included in the study and the experiments 




Efflux (MFI MFI )
(MFI MFI )
Drug accumulation MFI MFI
(with modulator sample) (without modulator sample)
(with modulator control) (without modulator control)
(without modulator sample) (without modulator control)
Statistical analyses. All the experiments were carried out in triplicates and means ± standard errors were 
reported. The obtained results were subjected to statistical analyses using Student’s t-test or one-way ANOVA 
with SPSS-22 software. Results that showed P-values less than 0.05 were considered to be statistically significant.
Data availability. The datasets generated and/or analyzed during the current study are available on request 
from the corresponding author.
Ethical approval. This article does not contain any studies with human participants or animals performed 
by any of the authors.
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